Background: Healthcare services provided to patients should vary depending on disease severity. However,
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive disease characterized by chronic dyspnea, cough, sputum production, and mainly attributed to long-term exposure to tobacco smoke.
COPD is the tenth-most common cause of death in Japan, and the number of associated deaths has exhibited an increasing trend [1] . The previous study estimated that 5 .3 million individuals aged ≥40 years were at risk of COPD in 2001 (estimated prevalence rate: 8.6%) [2] . In addition, statistical surveys reported that patients with COPD accounted for expenditures totaling 151 billion yen (approximately 0.4% of the Japanese total medical expenditures) in 2011 [3] .
Health insurance claims databases, which reflect real-world clinical environments, are important research tools with respect to drug safety monitoring, epidemiology and health economic studies. These databases include information about provided medical services, including disease diagnoses, procedures, and prescribed medications. Under the universal health insurance coverage system in Japan, patients can evenly use all available services, thus allowing the database collection of comprehensive information for patients living in Japan [4] . However, important clinical information is not included in these databases such as results of clinical test and disease severity. Appropriate treatment is provided according to a patient's medical needs, which are determined by the disease condition and/or severity [5] . In the absence of such information, estimated treatment effects determined through database studies are often biased due to confounding by indication [6] . Thus, when using health insurance claims, summary variables indicative of disease conditions or severity must be created using diagnostic code and/or prescribed medications. For example, the Charlson comorbidity index was developed to predict mortality [7] , and the Elixhauser comorbidity measure was developed to predict health-related outcomes [8] . COPD severity is generally assessed according to the results of respiratory function tests, using Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [9] .
In the present study, we focused on COPDrelated disease scores as a method of evaluating disease -specific costs and health service utilization. Various administrative database-focused COPD severity scores have been reported [10] [11] [12] , from among these, we selected a scoring system developed by Wu and colleagues that corresponded to our research purposes [10] . This score, which was developed in the United States (US) for patients with COPD who experience acute exacerbation events, was used to estimate drug utilization and medical costs related to COPD severity without relying on respiratory function test data [13] .
However, the patients evaluated in that study might have had a more severe disease condition, compared with the general population of Japanese patients with COPD. Moreover, drug selections for COPD management differ between the US and Japanese clinical environments: for example, the transdermal tulobuterol patch, a long-acting β2-agonist (LABA), has been frequently used in Japan for the long-term management of stable patients with COPD [14] . Therefore, we decided to modify the severity scoring system developed by Wu and colleagues to the Japanese clinical environment and validate this modification using a Japanese administrative database.
Methods

Settings and Data
This study used a health insurance claims database maintained by the Japan Medical Data Center (JMDC, Tokyo, Japan), which contains inpatient, outpatient, and pharmacy prescription records collected for approximately 2 million individuals since January 2005 [4] . A majority of insured persons listed in the database are employees of large companies or their family members [15] . This database is a useful resource 
Developing the Severity Score
The first claim involving a COPD diagnosis (ICD-10 codes: J42-J44) in 2011 was identified, and the month was defined as an index. Next, information about COPD related services provided to patients during the 12 -month period after the index month were extracted. We created nine variables: acute exacerbation event, emphysema diagnosis, asthma diagnosis with the medication, laboratory testing (respiratory function tests,
x-ray photography, or CT imaging), oxygen therapy, or prescribed anticholinergic, inhaled corticosteroid (ICS), short acting beta-agonist (SABA), and LABA agents [10] .
As no direct code indicating an acute exacerbation event in the insurance claims data, we created a proxy variable using information of an out-patient visit with a macrolide antibiotic/oral corticosteroid prescription or an emergency department visit with respiratory related diagnosis as used in previous studies [11] . We counted the number of variables that appeared in the monthly claims during the 12-month follow-up period (each variable range: 0-12). In addition, a continuous variable indicating patient age at COPD diagnosis was created using the patients' birth-year data.
A principal component analysis (PCA) was conducted to calculate factor loadings as weights [16] .
The PCA, a multivariate technique, is often used to reduce the number of variables. Each value of the relevant variables (age plus the nine variables indicated above) was multiplied by its own factor loading of the first principal component; these values were then summed to yield a severity score. For example, if the LABA factor loading was 0.6 and six LABA prescriptions were given in a year, the LABA score would be calculated as 0.6 × 6 = 3.6 points. Other points were similarly calculated and summed to yield each patient's original severity score. These scores were then standardized (mean: 50, standard deviation; 10)
according to the different units of the variables. The reliability of the estimated scores was assessed using
Cronbach's alpha [17] . In addition, we divided the severity scores into quartiles and calculated the mean value in each quartile to confirm increasing trends for each variable.
Predictive Performance
COPD severity score validity was confirmed by estimating the annual costs of COPD treatment and probability of an acute exacerbation event. We assumed that the calculated severity scores would be able to predict increased trends in these values. Many studies indicated that COPD costs and exacerbation risks were positively associated with the severity of a patient's severe/very severe: 6%) [2] . A linear trend test was conducted to confirm increased trends in COPD treatment costs and acute exacerbation risks [21, 22] .
Results
Patient Characteristics
We identified 1,784 patients with COPD diagnostic codes in 2011 (Fig 1) . The following patients 
Developing the Severity Score
PCA results are summarized in Table 2 . Among the ten variables, the factor loadings of LABA and ICS were most reflective of the severity of COPD conditions (0.50 and 0.49, respectively). Cronbach's alpha value was 0.60. Patients were categorized into quartiles according to scores (Q1 and Q4 were the lowest and highest scores, respectively). The mean value of the counted variables was calculated for each group (Table   3) , and the results indicated increased trends in higher severity score quartiles.
Predictive performance
Severity scores were re-calculated in the validating group (n = 300), using factor loadings from the development step. Distribution scores ranged from 4 to 34 and were similar between the developing and validating groups, as shown in Fig 2. When severity scores were divided into three categories, mild, moderate, and severe/very severe, the median costs were 79,027 yen, 204,445 yen, and 422,463 yen, respectively, indicating an increasing trend (p for trend < 0.05, Fig 3) . In addition, a similar increasing trend was observed for the risk of an acute exacerbation event (48%, 61%, and 83%, respectively; Fig 4) .
Discussion
Brief Statement of the Principal Findings
This study developed a COPD severity classification method using a Japanese administrative database and validated the performance of this method.
Score validity was confirmed by estimating COPD treatment costs and acute exacerbation risks, with higher scores indicating worse COPD conditions. Accordingly, this severity classification system could be used as a risk adjustment factor to control for potential confounders in administrative database studies.
Comparison with Similar Studies
Few attempts to classify COPD conditions in an administrative database have been published. Notably, Macaulay and colleagues reported that they had classified COPD patients into three severity groups according to spirometry test results and GOLD criteria in a study based on an electronic health records database linked to a health care claims database [12] . As their database included respiratory function test results, the authors were able to define COPD severity based on GOLD criteria. In addition, Mapel and colleagues C03, C07-9, or C011; ischemic heart disease was I20-25 with C01, C07-10, or B01; and diabetes was E10-14 with A10.
developed a method for identifying and characterizing COPD [11] . These authors stratified patients according to comorbid respiratory conditions and medical procedures but used coding systems unique to the US (such as ICD-9 and CPT-4 codes), with no counterparts in Japanese claims systems, to define COPD severity.
Moreover, Eisner and colleagues created COPD severity scores that used patient survey data but did not require respiratory function tests [23] . That scoring system, however, required health-related quality of life and physical disability-related information that are rarely included in administrative databases. As a result, a coding system that required neither the results of respiratory function tests nor patient-reported outcomes was required.
Wu and colleagues previously developed a classification method using a claims database in the US [10] . Their research included 2,068 patients with an acute exacerbation of chronic bronchitis due to COPD.
Twelve variables were selected to calculate COPD severity scores: number of days of hospitalization due to acute exacerbation; number of claims for oxygen therapy, acute exacerbation, emphysema, spirometry test, pulmonologist visit; prescriptions of anticholinergic, oral corticosteroid, ICS, SABA, and LABA agents; and patient age. The method developed by Wu and colleagues was later used to examine the utilization and cost of medical services according to COPD severity [13] , and was validated using another administrative database, although no direct comparison of respiratory function test values was performed [24] .
In our study, we added asthma variable and excluded three variables (hospitalization due to acute exacerbation, pulmonologist visit, and use of oral corticosteroid) from the method described by Wu and colleagues to increase score reliability for the following reasons. First, asthma is an important risk factor of COPD. Our study population had approximately 50% of asthma diagnosis. Second, our database included longterm hospitalized patients who required no aggressive treatments. Third, not all patients received COPD services from pulmonologists; some occasionally received services from doctors in other departments. In addition, when patients received COPD services from large hospitals, codes indicative of the doctors' specialties were often missing. Last, the oral corticosteroid variable was used to define an acute exacerbation event.
In our study, prescriptions of anticholinergic, LABA, and ICS agents were strongly associated with higher severity scores. However, this trend was in However, we did not remove these variables because they were very important indicators of COPD severity. In addition, the data included in the JMDC database were collected through the insurance reimbursement process; therefore, information is rarely missing. Moreover, under the Japanese national health insurance program, all services provided to COPD patients should be almost fully covered. For these reasons, our classification method was developed using all records of COPD treatment provided to Japanese patients.
However, this study also included limitations common to administrative database studies [10, 12] .
Notably, we did not consider the risk factor of smoking history, because the variable was not available in our database. Even without considering the data, our method was capable of describing COPD severity with regard to age and other treatment procedures.
Approximately 50% of patients in our study had comorbid asthma. It is difficult to clinically distinguish COPD from asthma, and therefore these diagnoses often overlap (asthma-COPD overlap syndrome). In previous research showed the prevalence of asthma-COPD overlap syndrome was 1.8-56.0% [25] [26] [27] [28] . Therefore, we did not remove patients with asthma from the study population.
Implications for Research
PCA often faces problems related to the low reproducibility of factor loading as a score system basis.
Reproducibility depends on treatment patterns in a database. Therefore, when using different data sources, researchers should re-calculate factor loading, as demonstrated in our study. Furthermore, additional studies in which our findings are applied for clinical usage are needed. We will compare the performance of COPD severity scores and clinical conditions using electronic health records at a large-scale hospital in Japan. The severity scores calculated from factor loadings in this study are relative values and cannot be used for distributions of COPD severities (i.e.,
proportions of mild vs. more severe conditions).
Therefore, we will set the cut-off values according to the GOLD criteria. These criteria allow the classification of COPD conditions into four severity categories depending on the values of respiratory function tests. We will evaluate the scores using the c-statistic, positive predictive value, or negative predictive value according to the electronic health records database. These techniques have been used previously to assess model discrimination and validate severity classification methods [29] [30] [31] .
Conclusion
In this study, a COPD severity classification method based on an administrative database in Japan was developed. This method is able to estimate COPD conditions without requiring laboratory test or clinical symptom data. For clinical implementation, we will confirm the validity of this classification system through comparison with medical information, including laboratory data. This classification method is a very
